Literature DB >> 23312388

A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds.

Changguang Wang1, Noelle S Williams.   

Abstract

The aim of this study is to further validate the use of ultrafiltration (UF) as a method for determining plasma protein binding (PPB) by demonstrating that non-specific binding (NSB) is not a limitation, even for highly lipophilic compounds, because NSB sites on the apparatus are passivated in the presence of plasma. Mass balance theory was used to calculate recovery of 20 commercial and seven investigational compounds during ultrafiltration in the presence and absence of plasma. PPB was also measured using this mass balance approach for comparison to PPB determined by rapid equilibrium dialysis (RED) and as found in the literature. Compound recovery during UF was dramatically different in the presence and absence of plasma for compounds with high NSB in PBS only. A comparison of PPB calculated by ultrafiltration with literature values or calculated by RED gave concordant results. Discrepancies could be explained by changes in pH, insufficient time to equilibrium, or compound instability during RED, problems which were circumvented by ultrafiltration. Therefore, NSB, as measured by the traditional incubation of compound in PBS, need not be an issue when choosing UF as a PPB assay method. It is more appropriate to calculate compound recovery from the device in plasma as measured by mass balance to determine the suitability of the method for an individual compound. The speed with which UF can be conducted additionally avoids changes in pH or compound loss that can occur with other methods. The mass balance approach to UF is thus a preferred method for rapid determination of PPB.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23312388      PMCID: PMC3545278          DOI: 10.1016/j.jpba.2012.11.018

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  20 in total

1.  Evaluation of in situ albumin binding surfaces: a study of protein adsorption and platelet adhesion.

Authors:  Sanjukta Guha Thakurta; Anuradha Subramanian
Journal:  J Mater Sci Mater Med       Date:  2010-12-01       Impact factor: 3.896

2.  Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids.

Authors:  Simon Taylor; Andy Harker
Journal:  J Pharm Biomed Anal       Date:  2005-11-28       Impact factor: 3.935

3.  Impact of pH on plasma protein binding in equilibrium dialysis.

Authors:  Christopher J Kochansky; Daniel R McMasters; Ping Lu; Kenneth A Koeplinger; Haley H Kerr; Magang Shou; Kenneth R Korzekwa
Journal:  Mol Pharm       Date:  2008-03-18       Impact factor: 4.939

4.  Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry.

Authors:  Yuzhong Deng; Harvey Wong; Richard A Graham; Wenbin Liu; Heuy-shin Shen; Yao Shi; Laixin Wang; Min Meng; Vikram Malhi; Xiao Ding; Brian Dean
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-06-12       Impact factor: 3.205

5.  Studies on paracetamol binding to serum proteins.

Authors:  T P Milligan; H C Morris; P M Hammond; C P Price
Journal:  Ann Clin Biochem       Date:  1994-09       Impact factor: 2.057

6.  Development of proneurogenic, neuroprotective small molecules.

Authors:  Karen S MacMillan; Jacinth Naidoo; Jue Liang; Lisa Melito; Noelle S Williams; Lorraine Morlock; Paula J Huntington; Sandi Jo Estill; Jamie Longgood; Ginger L Becker; Steven L McKnight; Andrew A Pieper; Jef K De Brabander; Joseph M Ready
Journal:  J Am Chem Soc       Date:  2011-01-06       Impact factor: 15.419

7.  Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.

Authors:  R Scott Obach; Franco Lombardo; Nigel J Waters
Journal:  Drug Metab Dispos       Date:  2008-04-21       Impact factor: 3.922

8.  Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding.

Authors:  Nigel J Waters; Rachel Jones; Gareth Williams; Bindi Sohal
Journal:  J Pharm Sci       Date:  2008-10       Impact factor: 3.534

9.  Targeting QseC signaling and virulence for antibiotic development.

Authors:  David A Rasko; Cristiano G Moreira; De Run Li; Nicola C Reading; Jennifer M Ritchie; Matthew K Waldor; Noelle Williams; Ron Taussig; Shuguang Wei; Michael Roth; David T Hughes; Jason F Huntley; Maggy W Fina; John R Falck; Vanessa Sperandio
Journal:  Science       Date:  2008-08-22       Impact factor: 47.728

10.  Structure-activity relationship studies of small-molecule inhibitors of Wnt response.

Authors:  Jianming Lu; Zhiqiang Ma; Jen-Chieh Hsieh; Chih-Wei Fan; Baozhi Chen; Jamie C Longgood; Noelle S Williams; James F Amatruda; Lawrence Lum; Chuo Chen
Journal:  Bioorg Med Chem Lett       Date:  2009-04-18       Impact factor: 2.823

View more
  12 in total

1.  Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC).

Authors:  Wentian Wang; Lu Zhang; Lorraine Morlock; Noelle S Williams; Jerry W Shay; Jef K De Brabander
Journal:  J Med Chem       Date:  2019-05-09       Impact factor: 7.446

2.  Preclinical Pharmacokinetics, Tissue Distribution and in vitro Metabolism of FHND6091, a Novel Oral Proteasome Inhibitor.

Authors:  Xu Yang; Amin Liu; Lin Yang; Tiantian Wen; Jia Wang; Jingmiao Shi; Hui Zhou; Zhimeng Chen; Meng Lei; Yongqiang Zhu
Journal:  Drug Des Devel Ther       Date:  2022-09-13       Impact factor: 4.319

3.  Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase.

Authors:  Shih-Chia Tso; Wen-Jun Gui; Cheng-Yang Wu; Jacinta L Chuang; Xiangbing Qi; Kristen J Skvora; Kenneth Dork; Amy L Wallace; Lorraine K Morlock; Brendan H Lee; Susan M Hutson; Stephen C Strom; Noelle S Williams; Uttam K Tambar; R Max Wynn; David T Chuang
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

4.  Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models.

Authors:  Ruhul Kayesh; Taleah Farasyn; Alexandra Crowe; Qiang Liu; Sonia Pahwa; Khondoker Alam; Sibylle Neuhoff; Oliver Hatley; Kai Ding; Wei Yue
Journal:  J Pharm Sci       Date:  2020-06-23       Impact factor: 3.534

5.  Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.

Authors:  Yue Huang; Rui Su; Yue Sheng; Lei Dong; Ze Dong; Hongjiao Xu; Tengfeng Ni; Zijie Scott Zhang; Tao Zhang; Chenying Li; Li Han; Zhenyun Zhu; Fulin Lian; Jiangbo Wei; Qiangqiang Deng; Yungui Wang; Mark Wunderlich; Zhiwei Gao; Guoyu Pan; Dafang Zhong; Hu Zhou; Naixia Zhang; Jianhua Gan; Hualiang Jiang; James C Mulloy; Zhijian Qian; Jianjun Chen; Cai-Guang Yang
Journal:  Cancer Cell       Date:  2019-04-15       Impact factor: 38.585

6.  Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent.

Authors:  Xin Tian; Hong-Meng Li; Jing-Yao Wei; Bing-Jie Liu; Yu-Hai Zhang; Gao-Ju Wang; Jun-Biao Chang; Hai-Ling Qiao
Journal:  Front Pharmacol       Date:  2016-08-18       Impact factor: 5.810

7.  Immobilised histidine tagged β2-adrenoceptor oriented by a diazonium salt reaction and its application in exploring drug-protein interaction using ephedrine and pseudoephedrine as probes.

Authors:  Qian Li; Liujiao Bian; Xinfeng Zhao; Xiaokang Gao; Jianbin Zheng; Zijian Li; Youyi Zhang; Ru Jiang; Xiaohui Zheng
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

8.  Discovery of a neuroprotective chemical, (S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with improved druglike properties.

Authors:  Jacinth Naidoo; Hector De Jesus-Cortes; Paula Huntington; Sandi Estill; Lorraine K Morlock; Ruth Starwalt; Thomas J Mangano; Noelle S Williams; Andrew A Pieper; Joseph M Ready
Journal:  J Med Chem       Date:  2014-04-16       Impact factor: 7.446

9.  Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.

Authors:  John T Isaacs; Susan L Dalrymple; D Marc Rosen; Hans Hammers; Anders Olsson; Tomas Leanderson
Journal:  Oncotarget       Date:  2014-09-30

Review 10.  Study on the interaction between active components from traditional Chinese medicine and plasma proteins.

Authors:  Qishu Jiao; Rufeng Wang; Yanyan Jiang; Bin Liu
Journal:  Chem Cent J       Date:  2018-05-04       Impact factor: 4.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.